Evidence map›Paper›PMID 29648575›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018

Early evolutionary divergence between papillary and anaplastic thyroid cancers.

J Capdevila, R Mayor, F M Mancuso, C Iglesias, G Caratù, I Matos, C Zafón, J Hernando, A Petit, P Nuciforo and 7 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

J CapdevilaVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
R MayorVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
F M MancusoVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
C IglesiasVall d Hebron Institute of Research (VHIR), Vall d'Hebron University Hospital, Barcelona.
G CaratùVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
I MatosVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
C ZafónVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
J HernandoVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
A PetitIDIBELL, Department of Pathology, Hospital Universitari de Bellvitge Universidad de Barcelona, Barcelona.
P NuciforoVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona.
J M Cameselle-TeijeiroClinical University Hospital, University of Santiago de Compostela, Santiago de Compostela.
C ÁlvarezClinical University Hospital, University of Santiago de Compostela, Santiago de Compostela.
J A RecioVall d Hebron Institute of Research (VHIR), Vall d'Hebron University Hospital, Barcelona.
J TaberneroVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona; CIBERONC, Barcelona; Universitat Autònoma de Barcelona, Cerdanyola del Vallès.
X Matias-GuiuIDIBELL, Department of Pathology, Hospital Universitari de Bellvitge Universidad de Barcelona, Barcelona; CIBERONC, Barcelona; Department of Pathology, Hospital Universitari Arnau de Vilanova de Lleida University of Lleida, IRBLleida, Lleida.
A VivancosVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona. Electronic address: avivancos@vhio.net.
J SeoaneVall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital, Barcelona; CIBERONC, Barcelona; Universitat Autònoma de Barcelona, Cerdanyola del Vallès; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Electronic address: jseoane@vhio.net.
Vall d'Hebron Institute of OncologyHebron University · PSUniversidade de Santiago de Compostela · ESBiomedical Research Institute of Lleida · ESCentro de Investigación Biomédica en Red de Cáncer · ESInstitut d'Investigació Biomédica de Bellvitge · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Papillary thyroid cancer (PTC) is the most common thyroid carcinoma and exhibits an almost uniformly good prognosis, while anaplastic thyroid cancer (ATC) is less frequent and is one of the most aggressive cancers usually resistant to conventional treatment. Current hypothesis posits that ATC derives from PTC through the progressive acquisition of a discrete number of genomic alterations and implies that the mutational landscape of ATC resembles that of PTC. However, the clinical behaviour of ATC and PTC is radically different. We decided to address the disconnection between the clinical behaviour of ATC and PTC and the proposed model of the progressive development of ATC from PTC. Patients and methods: We carried out exome sequencing of DNA from 14 ATC specimens including three cases of concomitant ATC and PTC as well as their corresponding normal DNA from 14 patients. The sequencing results were validated using droplet digital PCR. We carried out immunohistochemistry and immunofluorescence studies of the concomitant ATC and PTC cases. In addition, we integrated our sequencing results with the existing TCGA data. Results: Most of the somatic mutations identified in the ATC component differed from the ones in PTC in the cases of concomitant ATC and PTC. The trunks of the phylogenetic trees representing the somatic mutations were short with long branches. In one case of concomitant PTC and ATC specimens, we observed an infiltration of PTC cells within the ATC component. Moreover, we integrated our results with data obtained from TCGA and observed that the most frequent mutations found in ATC presented high cancer cell fraction values and were significantly different from the PTC ones. Conclusion: ATC diverge from PTC early in tumour development and both tumour types evolve independently. Our work allows the understanding of the relationship between ATC and PTC facilitating the clinical management of these malignancies.

Indexed as

Clonal EvolutionBiomarkers, TumorExome SequencingHumansMutationPhylogenyPrognosisThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticThyroid NeoplasmsBiomarkers, Tumor

Identifiers

PMID29648575
OpenAlexW2796649038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.